Temedica, a Munich-based health insights company, has raised €25M in a Series B funding round led by MIG Capital and a Munich-based family office. The latest round brings the total fund raised to date to €42M.
The company will use the funds to accelerate the expansion of its ecosystem, which provides holistic insights into the care realities and patient journeys of millions of patients by combining health-related data, and its development efforts.
Gloria Seibert, founder & CEO of Temedica, says, “Temedica’s vision is to make a pioneering contribution to the development of personalised medicine by linking health-relevant data to new, evidence-based insights. We are convinced that big data sets and completely new data types, such as patient-generated data from large populations outside of classic clinical trials, play a key role. These enable new knowledge and understanding of diseases and their actual courses. I am very pleased that our investors share this vision and accompany and support us as we continue to expand the Temedica ecosystem.”
Health insight platform
Established by Gloria Seibert and Benjamin Friedrich in 2016, Temedica is a health insights company whose mission is to enable personalised and individualised medicine, focusing on patients and their needs.
The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.
From more than 40 billion data points on over 50,000 diagnoses, the German company derives health-related insights on issues such as disease progression, treatment effectiveness, patient journeys, and medication adherence.
The Temedica ecosystem brings together data from various sources, such as registry data, sales data of medically relevant products, insurance data, patient experience data, and – with explicit patient consent – patient-generated data from patient companion apps.
As per the company’s claims, the information and insights collected by them are channeled back to patients via Temedica’s patient companion apps.
Boris Bernstein, Partner at MIG Capital, says, “Temedica is operating in a massively growing and highly attractive market. The newly developed real-world insights platform Permea provides pharmaceutical companies with a deep understanding of patients and their care in the real world, outside of clinical trials. Access to this unique 360° understanding of care realities has the potential to revolutionize our healthcare system as we know it. The team at Temedica is highly motivated and goal-oriented, and we are excited to work with them and continue our journey together.”
